DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...

The dispute centers on Medtronic’s InterStim device, an implanted neurostuimulator used to treat patients with an overactive bladder and bowel-control conditions. On Thursday, Medtronic filed a ...

Certain healthcare conditions often go unspoken, leading to silent struggles that affect the lives of many. Overactive bladder (OAB) and fecal incontinence (FI) are two such conditions, impacting ...

NASHVILLE, Tenn. (Ivanhoe Newswire) – It’s a taboo topic that nobody talks about but, almost one in six Americans suffer with urinary or bowel incontinence. That’s more than the number of people with ...

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...

(WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the number of people with Alzheimer’s, diabetes, or breast ...

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...

One in six adults have bladder control problems. It can disrupt sleep or cause accidents, lead to social isolation and depression and affects women more than men. Overactive bladder syndrome affects ...